NCT04528407 2025-02-13
BS-FU01 Follow-Up Study of FluBHPVE6E7 Study Subjects
BlueSky Immunotherapies GmbH
Completed
Clinical Trials
3 trialsNCT03152526 2020-07-09
CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR
Miltenyi Biomedicine GmbH
Phase NA Terminated
NCT01219192 2010-10-28
Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure
Protgen Ltd
Phase 1 Unknown